Alexandria Real Estate Equities (NYSE: ARE) is the life-science landlord that invented the category: mega-campus lab clusters in Boston, San Francisco, and San Diego serving pharma and biotech, currently the deepest value debate in REITs after a lab-supply glut and biotech funding winter crushed the stock while the dividend kept growing.
| Alexandria Real Estate Equities (ARE) Snapshot | |
|---|---|
| Share Price (delayed) | $48.38 +0.63% |
| Market Cap | $8.4B |
| Annualized Dividend | $3.48 (Quarterly) |
| Dividend Yield | 7.24% |
| Credit Rating | BBB+ (S&P) |
| Sector | Office ยท Life Science |
Market data updates automatically several times daily. Last price refresh: Jul 14, 2026.
Business Model and the Glut
Alexandria’s clusters house the industry that cannot work from home: wet labs for Big Pharma, funded biotechs, and research institutions on long leases. The problem is supply: everyone piled into lab development during the biotech bubble, deliveries flooded exactly as venture funding froze, and vacancy in ARE’s markets rose for the first time in its history, compressing occupancy and forcing asset sales at prices bears cite and bulls dispute.
Dividend Safety Analysis
The dividend has grown for over a decade and continued growing through the drawdown, covered by FFO at conservative ratios with BBB+ credit. The payout is not the debate; the trajectory of NAV and lab rents is.
The Honest Risk Section
Supply digestion takes years, big pharma is consolidating footprints exactly when it shouldn’t be, and every asset sale reprices the private-market comp debate. The bull case (irreplaceable clusters, tenant credit, demographic-driven drug demand, a covered growing dividend at a generational-low multiple) is genuinely strong; so was the bear case for the last three years. Deep value with a real coupon while you wait.
Frequently Asked Questions
Why has Alexandria’s stock fallen so much?
A lab-space supply glut met a biotech funding winter, raising vacancy in its core clusters for the first time and forcing the market to reprice growth assumptions built over two decades.
Is ARE’s dividend safe?
Coverage remains conservative on BBB+ credit and the dividend kept growing through the entire drawdown; the equity debate is about asset values, not the payout.
Analysis based on company disclosures through Q1 2026. Live market data updates automatically. Independent research, not investment advice.